Data compiled by Redley Lamar · ChainSifter Intelligence
2Suppliers
5Customers
1Debt Items
0Related Chains
Source-Backed Evidence Depth
Anebulo Pharmaceuticals, Inc. (ANEB) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
9Total relationships
2Distinct source URLs
4High confidence
0.744Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Anebulo Pharmaceuticals, Inc. Suppliers
Ticker
Name
Confidence
Evidence
VERNALIS
VERNALIS
90%
We have access to certain regulatory materials, including study reports from clinical and non-clinical trials, under Vernalis' control.
VERNALIS-DEVELOPMENT-LIMITED
VERNALIS-DEVELOPMENT-LIMITED
90%
The Company licensed certain intellectual property, know-how and clinical trial data from Vernalis Development Limited
Anebulo Pharmaceuticals, Inc. Customers
Ticker
Name
Confidence
Evidence
JFL-CAPITAL-MANAGEMENT-LLC
JFL-CAPITAL-MANAGEMENT-LLC
62%
Product candidates currently under development will require significant additional research and development efforts, including extensive nonclinical and clinical testing and regulatory approval prior…
NASDAQ-STOCK-MARKET-LLC
NASDAQ-STOCK-MARKET-LLC
62%
Product candidates currently under development will require significant additional research and development efforts, including extensive nonclinical and clinical testing and regulatory approval prior…
ORGANIZATION-ANEBULO-PHARMACEUTICALS-INC
ORGANIZATION-ANEBULO-PHARMACEUTICALS-INC
62%
uirements, expenses and other operating results, and needs for additional financing; ● the timing or outcome of any of our regulatory submissions; ● our ability to obtain funding, including grant fun…
R-D-LIMITED
R-D-LIMITED
62%
etion of our ongoing and planned clinical trials and nonclinical studies; ● our ability to receive, and the timing of receipt of, future regulatory approvals for our product candidates and the costs …
VERNALIS-DEVELOPMENT-LIMITED
VERNALIS-DEVELOPMENT-LIMITED
62%
etion of our ongoing and planned clinical trials and nonclinical studies; ● our ability to receive, and the timing of receipt of, future regulatory approvals for our product candidates and the costs …
Anebulo Pharmaceuticals, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
ANEB-DEBT-7757
Warrants outstanding: 26626710
90%
xbrl warrant detail from xbrl 2021-06-30.
Anebulo Pharmaceuticals, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Anebulo Pharmaceuticals, Inc..
Anebulo Pharmaceuticals, Inc. Ownership
Holder
Name
Confidence
Evidence
ANEB-OWNER-MORGAN-STANLEY
MORGAN STANLEY
90%
13F overlay lists MORGAN STANLEY as top holder; 2 tracked holders.
Anebulo Pharmaceuticals, Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
